Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients

Fig. 4

Spleen and tumor uptake (SUVpeak (A) and SUVmax (B)) of [68Ga]Ga-DOTATATE and [68Ga]Ga-HA-DOTATATE for: (C) control group, (1) limited disease, (2) liver-only metastases and (3) extensive metastases patients. Lines indicate significant uptake differences between two groups (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001)

Back to article page